NBW Capital LLC Has $2.60 Million Position in Repligen Corporation (NASDAQ:RGEN)

Key Points

• NBW Capital LLC reduced its stake in Repligen Corporation by 18.9% during the first quarter, now holding 20,432 shares valued at $2.6 million.
• Repligen's recent earnings report showed a quarterly revenue of $182.37 million, exceeding analyst estimates, even though EPS of $0.37 fell short of expectations.
• Majority institutional ownership stands at 97.64%, with several hedge funds adjusting their stakes, indicating significant interest in the company.

NBW Capital LLC reduced its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,432 shares of the biotechnology company's stock after selling 4,762 shares during the quarter. NBW Capital LLC's holdings in Repligen were worth $2,600,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in RGEN. Raiffeisen Bank International AG acquired a new stake in Repligen in the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen during the fourth quarter worth $40,000. Signaturefd LLC raised its holdings in shares of Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. raised its holdings in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares during the period. Finally, UMB Bank n.a. grew its position in shares of Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 332 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

RGEN traded down $2.09 during trading on Friday, reaching $111.43. 635,942 shares of the company's stock were exchanged, compared to its average volume of 1,059,227. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average price of $122.76 and a 200 day moving average price of $134.12. The company has a market capitalization of $6.26 billion, a P/E ratio of -445.70, a PEG ratio of 2.05 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the business earned $0.40 earnings per share. The company's revenue for the quarter was up 14.8% on a year-over-year basis. As a group, analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on RGEN shares. Wells Fargo & Company decreased their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Barclays started coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. Finally, Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target for the company in a research report on Tuesday, July 22nd. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and an average price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.